FCM
HRTX icon

Farallon Capital Management’s Heron Therapeutics HRTX Stock Holding History

Farallon Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-875,000
Closed -$20.6M – 109
2019
Q4 		$20.6M Buy
+875,000
New +$19.4M 0.14% 86

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Farallon Capital Management's HRTX Position: Q1 2020 in Review

Farallon Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2020, closing a stake of 875,000 shares — an estimated $20.6M sold.

Farallon Capital Management first reported a position in HRTX in Q4 2019 and held it in 1 quarter. The position peaked at $20.6M in Q4 2019. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2020.

  • Farallon Capital Management reported no remaining Heron Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Farallon Capital Management sold 875,000 Heron Therapeutics shares in Q1 2020, an estimated $20.6M.
  • Farallon Capital Management first reported a position in Heron Therapeutics in Q4 2019 and held it in 1 quarter.
  • Farallon Capital Management's Heron Therapeutics position peaked at $20.6M in Q4 2019.
  • 193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.